phenformin has been researched along with Bile Duct Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Jaidee, R; Kongpetch, S; Kukongviriyapan, U; Kukongviriyapan, V; Prawan, A; Senggunprai, L | 1 |
Cheng, Q; Feng, F; Gan, W; Hu, S; Jiang, X; Ouyang, Q; Qiao, L; Shi, Y; Wang, J; Wu, D | 1 |
2 other study(ies) available for phenformin and Bile Duct Cancer
Article | Year |
---|---|
Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Culture Media, Conditioned; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neovascularization, Physiologic; Oxidative Stress; Phenformin; Phosphorylation; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2020 |
Phenformin inhibits cell proliferation and induces cell apoptosis and autophagy in cholangiocarcinoma.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; Humans; Male; Mice; Phenformin; Protein Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |